Ragheb AlShakhshir - Hikma Pharmaceuticals Corporate Vice President - Research & Development

HKMPF Stock  USD 23.37  0.47  2.05%   

President

Mr. Ragheb AlShakhshir is Corporationrationrate Vice President Research Development of Hikma Pharmaceuticals Plc. Ragheb joined Hikma as a Research and Development Manager. Prior to joining Hikma he held a variety of roles as Senior Scientist at Novartis Pharmaceuticals and at Alcon Labs in the US. From 20032008 Ragheb led the Hikma RD Injectables team and from February 2009 assumed the responsibility of Corporationrationrate Vice President Research and Development. Ragheb has a PhD in Industrial and Physical Pharmacy from Purdue University a Masters in Engineering from the University of Massachusetts Amherst and a BSc in Chemical Engineering from the University of WisconsinMadison. since 2009.
Tenure 15 years
Phone44 20 7399 2760
Webhttps://www.hikma.com

Hikma Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 651 M in total debt with debt to equity ratio (D/E) of 0.71, which is about average as compared to similar companies. Hikma Pharmaceuticals PLC has a current ratio of 2.08, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hikma Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Hikma Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hikma Pharmaceuticals PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hikma to invest in growth at high rates of return. When we think about Hikma Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Anna MarrsAmerican Express
47
Richard PetrinoAmerican Express
56
Neal SampleAmerican Express
39
Paul AbbottAmerican Express
N/A
Linda ZukauckasAmerican Express
N/A
Elizabeth RutledgeAmerican Express
62
Paul FabaraAmerican Express
52
James BushAmerican Express
57
Michael OneillAmerican Express
64
John HayesAmerican Express
60
Ashwini GuptaAmerican Express
62
Marc GordonAmerican Express
59
Denise PickettAmerican Express
55
Rick PetrinoAmerican Express
N/A
Susan SobbottAmerican Express
51
Laureen SeegerAmerican Express
62
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people. Hikma Pharmaceuticals PLC [HKMPF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Hikma Pharmaceuticals PLC Leadership Team

Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients
Bassam Kanaan, Chief Strategy & Corporate Development Officer
Khalid Nabilsi, Chief Officer
Hussein Arkhagha, General Counsel
Susan Ringdal, Vice President - Corporate Strategy and Investor Relations
Pamela Kirby, Non-Executive Independent Director
John Castellani, Non-Executive Independent Director
Brian Hoffman, President and Chief Executive of - Generics Division
Ali AlHusry, Non-Executive Director
Jochen Gann, Non-Executive Director
Engineer Darwazah, Ex CEO
Peter Speirs, Company Secretary
Patrick Butler, Non-Executive Independent Director
Brian Hoffmann, Pres Generics
Said Darwazah, Chairman and CEO
Michael Raya, President and CEO, USA
Samuel Park, Global US
Ronald Goode, Non-Executive Independent Director
Bryan Hotston, CIO
Sigurdur Olafsson, CEO
Breffni Byrne, Non-Executive Independent Director
Nina Henderson, Non-Executive Independent Director
Cynthia Schwalm, Independent Non-Executive Director
Ragheb AlShakhshir, Corporate Vice President - Research & Development
Michael Ashton, Non-Executive Independent Director
Majda Labadi, Corporate Vice President - Human Resources
Ibrahim Jalal, Sr. Corporate VP of Technical Affairs
Riad Mishlawi, EU Vice President and Global Head - Injectables
Robert Pickering, Senior Non-Executive Independent Director
Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets
CPA CFA, Exec MA

Hikma Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Hikma Pink Sheet analysis

When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Please note, there is a significant difference between Hikma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hikma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hikma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.